Slamon, Dennis J.

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science

HER2/EGFR in Cancer ResearchBreast Cancer Treatment Studies

Cited by 11,760

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2

Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 11,500

Palbociclib and letrozole in advanced breast cancer

Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 3,007

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., et al. (2015) · Cell

interferon and immune responsesCancer Immunotherapy and Biomarkers

Cited by 2,022

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 1,900

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 1,860

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 1,827

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 1,398

Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer

Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Lin, N. U., Borges, V., Abramson, V., Anders, C., et al. (2020) · New England Journal of Medicine

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 1,326

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 1,276

Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3

Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2018) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 1,121

Overall survival with ribociclib plus fulvestrant in advanced breast cancer

Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2020) · New England Journal of Medicine

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 865

Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up

Rugo, H. S., Finn, R. S., Diéras, V., Ettl, J., Lipatov, O., Joy, A. A., Harbeck, N., Castrellon, A., Iyer, S., Lu, D. R., et al. (2019) · Breast Cancer Research and Treatment

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 443

Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

Slamon, D. J., Neven, P., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S., Petrakova, K., Valeria Bianchi, G., Martín, M., Nusch, A., et al. (2021) · Annals of Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 281

Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer

Hurley, J., Doliny, P., Reis, I., Silva, O., Gomez-Fernandez, C., Velez, P., Pauletti, G., Powell, J. E., Pegram, M. D., & Slamon, D. J. (2006) · Journal of Clinical Oncology

HER2/EGFR in Cancer ResearchBreast Cancer Treatment Studies

Cited by 245

HER‐2/ neu Signal Transduction in Human Breast and Ovarian Cancer

Reese, D. M., & Slamon, D. J. (1997) · STEM CELLS

HER2/EGFR in Cancer ResearchPI3K/AKT/mTOR signaling in cancer

Cited by 229

Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

Cristofanilli, M., Rugo, H. S., Im, S.-A., Slamon, D. J., Harbeck, N., Bondarenko, I., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., et al. (2022) · Clinical Cancer Research

Advanced Breast Cancer TherapiesPARP inhibition in cancer therapy

Cited by 207

Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer

Slamon, D. J., Diéras, V., Rugo, H. S., Harbeck, N., Im, S.-A., Gelmon, K. A., Lipatov, O. N., Walshe, J. M., Martin, M., Chavez-MacGregor, M., et al. (2024) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesPARP inhibition in cancer therapy

Cited by 200

Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2.

Finn, R. S., Rugo, H. S., Dieras, V. C., Harbeck, N., Im, S.-A., Gelmon, K. A., Walshe, J. M., Martin, M., Chavez Mac Gregor, M., Bananis, E., et al. (2022) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 169

Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients

Hurvitz, S. A., Betting, D. J., Stern, H. M., Quinaux, E., Stinson, J., Seshagiri, S., Zhao, Y., Buyse, M., Mackey, J., Driga, A., et al. (2012) · Clinical Cancer Research

HER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies Research

Cited by 115

Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response

McNamara, K. L., Caswell-Jin, J. L., Joshi, R., Ma, Z., Kotler, E., Bean, G. R., Kriner, M., Zhou, Z., Hoang, M., Beechem, J., et al. (2020) · Nature Cancer

HER2/EGFR in Cancer ResearchBreast Cancer Treatment Studies

Cited by 92

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.

Neven, P., Fasching, P. A., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Martín, M., Nusch, A., et al. (2023) · Breast Cancer Research

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 83

An integrated microfluidic device for rapid and high-sensitivity analysis of circulating tumor cells

Jiang, J., Zhao, H., Shu, W., Tian, J., Huang, Y., Song, Y., Wang, R., Li, E., Slamon, D., Hou, D., et al. (2017) · Scientific Reports

Microfluidic and Bio-sensing TechnologiesMicrofluidic and Capillary Electrophoresis Applications

Cited by 66

Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3.

Cristofanilli, M., Rugo, H. S., Im, S.-A., Slamon, D. J., Harbeck, N., Bondarenko, I., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., et al. (2021) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesPARP inhibition in cancer therapy

Cited by 65